Abstract

The entry of HIV into the human genome by integrase is the first step in the virus’s use of human host cell machinery to achieve its own replication and proliferation, which is also a key step in the entire virus infection cycle. Integrase inhibitor (INI) , represented by raltegravir (RAL) , elvitegravir (EVG) and dolutegravir (DTG) , plays an effective role in the antiviral action with a novel mechanism of action, but still fail to complete virus suppression persistently due to the emergence of INI resistance. The mutations in the three major HIV-1 integrase inhibitors and the effects of drug-resistant mutations on the integrase efficiency and the adaptability to virus replication are summarized in this review. Key words: HIV-1; Integrase inhibitors; Drug-resistant mutations; Enzyme efficiency; Replication adaptability

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.